# Precision BioSciences, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Precision BioSciences, Inc). ## Overview Precision BioSciences is a U.S.-based clinical-stage gene editing company built around its proprietary ARCUS genome editing platform. The company develops in vivo therapies for genetic and infectious diseases and also licenses ARCUS-related intellectual property to collaborators and other biotechnology companies. ## Products & services • ARCUS genome editing platform • In vivo gene editing therapies • Genetic disease product candidates • Infectious disease product candidates • ARCUS-related licensing and royalties • Research collaboration agreements - **ARCUS platform and therapeutic programs** (85%) — Development of proprietary genome editing tools and therapeutic candidates for human disease. - **Licensing and collaboration revenue** (15%) — Upfront payments, milestones, and royalties from partners using ARCUS-related IP. - ARCUS genome editing platform - In vivo gene editing therapies - Genetic disease product candidates - Infectious disease product candidates - ARCUS-related licensing and royalties - Research collaboration agreements ## Customers Precision BioSciences sells primarily to pharmaceutical and biotechnology partners through licensing and collaboration agreements, while its internal programs are aimed at future patients with genetic or infectious diseases. Its commercial counterparties are research-driven companies that need access to genome-editing IP, preclinical know-how, or therapeutic development rights. If approved, future products would be used by hospitals, specialists, and treatment centers rather than sold directly to consumers. - **Biotechnology and pharmaceutical collaborators** (primary) — License ARCUS IP or partner on preclinical programs in exchange for upfront fees, milestones, and royalties. - **Future therapeutic end users** (secondary) — Patients with genetic or infectious diseases who would receive approved ARCUS-based therapies. - **Research and development partners** (secondary) — Companies and institutions that use ARCUS in discovery, preclinical, or translational work. - Biopharma partners licensing ARCUS for therapeutic development - Collaborators paying upfront fees, milestones, and royalties - Future patients with genetic diseases targeted by in vivo therapies - Future patients with infectious diseases targeted by gene editing - Hospitals and specialty treatment centers, if products are approved ## Geography Precision BioSciences is headquartered in the United States and conducts its research, development, and corporate activities from there. Its collaboration and licensing model can reach global partners, but the company’s operating footprint is centered on U.S.-based scientific and regulatory infrastructure. Because its programs are pre-commercial, geography matters mainly through where trials, partners, and regulatory approvals are pursued. - Headquartered in the United States - Core R&D and corporate operations are U.S.-based - Collaborations can extend to global biopharma partners - Future clinical development will depend on U.S. and foreign regulators - No country-level revenue disclosure was provided ## Strategy The company’s strategy is to advance ARCUS-based in vivo therapies while using partnerships and licensing to monetize its platform before full product commercialization. It also seeks to expand its intellectual property portfolio and manufacturing know-how so it can support future clinical and commercial development. These priorities are intended to preserve optionality across both internal drug development and external licensing. - **Advance ARCUS therapeutic pipeline** (medium-term) — Internal programs are the main path to long-term value creation and future product revenue. - **Monetize platform through licensing and collaborations** (short-term) — Partner deals can generate non-product revenue and external validation of ARCUS technology. - **Strengthen IP and development capabilities** (medium-term) — Genome editing is highly IP-intensive and requires strong preclinical and manufacturing execution. - Advance ARCUS-based in vivo therapeutic candidates - Use collaborations to fund development and validate the platform - Expand intellectual property around genome editing - Develop manufacturing processes for future clinical use - Build commercialization capability only if products reach approval ## Risks Precision BioSciences faces the typical risks of a clinical-stage gene editing company: uncertain clinical outcomes, regulatory approval risk, and heavy dependence on intellectual property protection. Its business also depends on third-party collaborators, contract research and manufacturing providers, and future access to capital, which can all affect timing and execution. As a pre-commercial company, it is also exposed to cybersecurity, patent, and biosimilar competition risks if any products are approved. - **Clinical development failure** [high] — Therapeutic candidates are still in development and may not show safety or efficacy. - **Regulatory approval risk** [high] — Gene editing products face stringent FDA and foreign review, with possible restrictions or denial. - **Intellectual property and license risk** [high] — The business depends on patents and license agreements that can expire or be challenged. - **Partner concentration and collaboration risk** [medium] — A meaningful part of revenue comes from collaboration accounting and partner milestones. - **Financing risk** [high] — The company has not generated product sales and relies on external capital to fund R&D. - **Cybersecurity and third-party execution risk** [medium] — R&D, manufacturing, and collaborator data flows depend on external systems and vendors. - Clinical trials may fail or take longer than expected - Regulatory approval may be delayed, limited, or denied - Patent disputes could weaken ARCUS exclusivity - Partner dependence can affect milestone and royalty revenue - Additional capital may be needed to fund operations - Cybersecurity or vendor disruptions could impair R&D ## Accounting The most important accounting issue is revenue recognition from collaboration and license agreements, where revenue can be recognized as performance obligations are satisfied or when deferred revenue is released. Because the company is pre-commercial, reported results can swing sharply based on milestone timing, contract conclusions, and the mix of upfront versus deferred revenue. Investors should also watch estimates tied to stock compensation, lease commitments, and any impairment or valuation judgments related to long-lived assets and intellectual property. - **Revenue recognition for collaboration and license agreements** — Can cause large fluctuations unrelated to current-period cash receipts - **Deferred revenue roll-off** — Major driver of year-to-year revenue variability - **Stock-based compensation** — Affects operating loss and comparability across periods - **Lease accounting and R&D commitments** — Affects balance sheet liabilities and operating expense timing - Collaboration and license revenue depends on contract timing - Deferred revenue can create large period-to-period swings - Milestones and contract conclusions affect reported revenue - Stock-based compensation is important for operating expense - Lease and asset estimates matter for a small R&D footprint --- *Last updated: 2026-04-29T04:46:44.068151+00:00*